Journal article
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Gyoergy Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella, Tudor Eliade Ciuleanu, G Pover, NC Tebbutt
Investigational New Drugs | SPRINGER | Published : 2012
Grants
Funding Acknowledgements
This was a phase II signal-searching study funded by AstraZeneca.